BOSTON – April 30, 2025 – PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of IBD Explore™ and AIM-HI UC™ at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA.1 IBD Explore is an AI-powered tool providing comprehensive and quantitative characterization of the inflammatory IBD microenvironment. AIM-HI UC™ is the only AI-powered Geboes scoring tool that assists pathologists in accurately and reproducibly measuring Geboes subgrades for histological stage and improvement to enable ulcerative colitis research and clinical trials.
PathAI has recently launched updated versions of these tools on the AISight Translational Research platform1. IBD Explore v2.0 includes classification of additional cell types and tissue regions that were not included in prior versions, including macrophages, fibroblasts, and lymphoid aggregates. AIM-HI UC v2.0 now integrates PathAI's pathology universal transformer (PLUTO) foundation model and shows highly accurate performance, as highlighted in poster Su1904 at DDW.
Poster Details
Title: Consortium-driven Development of Pathology Foundation Model-based Approaches for Automated Scoring of Histopathology in Ulcerative Colitis (Abstract Number Su1904)
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.
Footnote
1AIM-HI UC™, IBD Explore™, and AISight are For Research Use Only. Not for use in diagnostic procedures.
PathAI has recently launched updated versions of these tools on the AISight Translational Research platform1. IBD Explore v2.0 includes classification of additional cell types and tissue regions that were not included in prior versions, including macrophages, fibroblasts, and lymphoid aggregates. AIM-HI UC v2.0 now integrates PathAI's pathology universal transformer (PLUTO) foundation model and shows highly accurate performance, as highlighted in poster Su1904 at DDW.
Poster Details
Title: Consortium-driven Development of Pathology Foundation Model-based Approaches for Automated Scoring of Histopathology in Ulcerative Colitis (Abstract Number Su1904)
- Session: IBD: Disease Activity Assessment and Monitoring
- Date and Time: Sunday, May 4, 2025, from 12:30 – 1:30 p.m. PT
- Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI
- Session: Emerging Tools and Technologies and In Vivo Models of GI Diseases
- Date and Time: Tuesday, May 6, 2025, from 12:30 – 1:30 p.m. PT
- Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.
Footnote
1AIM-HI UC™, IBD Explore™, and AISight are For Research Use Only. Not for use in diagnostic procedures.
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
[email protected]
Media Contact
Daniel Donato
LifeSci Communications
[email protected]
516-474-0554
Company Contact
Liz Storti
Chief People Officer
[email protected]
Media Contact
Daniel Donato
LifeSci Communications
[email protected]
516-474-0554
